Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma
The Journal of Pharmacology and Experimental Therapeutics · 2023
DOI: 10.1124/jpet.123.001583 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023. Verfasst von Linyan Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: 1Blood Diseases Institute (L.X., M.Z., D.T., Z.L., T.L., Y.Z., S.Z., Y.M., D.Y., X.W., W.S.) and Key Laboratory of Bone Marrow Stem Cell (L.X., M.Z.,…. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Epstein-Barr Virus Infections, Lymphoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) is a type of human γ-herpesvirus, and its reactivation plays an important role in the development of EBV-driven Burkitt lymphoma (BL). Despite intensive chemotherapy, the prognosis of relapsed/refractory BL patients remains unfavorable, and a definitive method to completely eliminate latent EBV infection is lacking. Previous studies have demonstrated that histone deacetylase (HDAC) inhibitors can induce the transition of EBV from latency to the lytic phase. The lytic activation of EBV can be inhibited by tenofovir, a potent inhibitor of DNA replication. Herein, we explored the antitumor effect and EBV clearance potential of a novel HDAC inhibitor called chidamide, combined with tenofovir, in the treatment of EBV-positive BL. In the study, chidamide exhibited inhibitory activity against HDAC. Moreover, chidamide inhibited BL cell proliferation, arrested cell cycle progression, and induced BL cell apoptosis primarily by regulating the MAPK pathways. Additionally, chidamide promoted the transcription of lytic genes, including BZLF1, BMRF1, and BMLF1 Compared with chidamide alone, the addition of tenofovir further induced growth arrest and apoptosis in EBV-positive BL cells and inhibited the transcriptions of EBV lytic genes induced by chidamide alone. Furthermore, our in vivo data demonstrated that the combination of chidamide and tenofovir had superior tumor-suppressive effects in a mouse model of BL cell tumors. The aforementioned findings confirm the synergistic effect of chidamide combined with tenofovir in inducing growth inhibition and apoptosis in EBV-positive BL cells and provide an effective strategy for eliminating EBV and EBV-associated malignancies. SIGNIFICANCE STATEMENT: High levels of Epstein-Barr virus (EBV)-DNA have consistently been associated with unfavorable progression-free survival and overall survival in EBV-associated lymphomas. Therefore, identifying novel strategies to effectively eradicate tumor cells and eliminate EBV is crucial for lymphoma patients. This study confirmed, for the first time, the synergistic effect of chidamide combined with tenofovir in the treatment of Burkitt lymphoma and the eradication of EBV virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Blood Diseases Institute (L.X., M.Z., D.T., Z.L., T.L., Y.Z., S.Z., Y.M., D.Y., X.W., W.S.) and Key Laboratory of Bone Marrow Stem Cell (L.X., M.Z., D.T., Z.L., T.L., Y.Z., S.Z., Y.M., D.Y., X.W., W.S.), Xuzhou Medical…
ORCID-Profile: Linyan Xu
Zitieren
APA
Xu, L., Zhang, M., Tu, D., Lu, Z., Lu, T., Ma, D., Zhou, Y., Zhang, S., Ma, Y., Yan, D., Wang, X., & Sang, W. (2023). Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001583
Vancouver
Xu L, Zhang M, Tu D, Lu Z, Lu T, Ma D, et al. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma. The Journal of Pharmacology and Experimental Therapeutics. 2023. doi:10.1124/jpet.123.001583
BibTeX
@article{Xu2023,
author = {Xu, Linyan and Zhang, Meng and Tu, Dongyun and Lu, Ziyi and Lu, Tianyi and Ma, Dongshen and Zhou, Yi and Zhang, Shuo and Ma, Yuhan and Yan, Dongmei and Wang, Xiangmin and Sang, Wei},
title = {Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2023},
doi = {10.1124/jpet.123.001583}
}
EUVIMED